Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial ofd-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment

2006 ◽  
Vol 12 (3) ◽  
pp. 178-189 ◽  
Author(s):  
Karl Goodkin ◽  
Benedetto Vitiello ◽  
William D Lyman ◽  
Deshratn Asthana ◽  
J Hampton Atkinson ◽  
...  
2000 ◽  
Vol 44 (11) ◽  
pp. 3155-3157 ◽  
Author(s):  
Véronique Joly ◽  
Mauro Moroni ◽  
Ercole Concia ◽  
Adriano Lazzarin ◽  
Bernard Hirschel ◽  
...  

ABSTRACT We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.


1994 ◽  
Vol 70 (6) ◽  
Author(s):  
Marisa Márcia Mussi-Pinhata ◽  
Maria Célia C. Ferez ◽  
Dimas T. Covas ◽  
Geraldo Duarte ◽  
Márcia L. Isaac ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document